Lakewood-Amedex Biotherapeutics filings document its status as a Nevada clinical-stage biotechnology company and Nasdaq-listed issuer focused on Bisphosphocin antimicrobial compounds. The company’s S-1 registration materials cover securities registration, business description, capitalization, risk factors, and offering-related disclosures for LABT common stock.
Material-event filings include governance disclosures such as director appointments and board matters reported under Form 8-K. The filing record also identifies public-company information related to corporate structure, pharmaceutical-preparations classification, executive offices, and securities-law reporting obligations.
Lakewood-Amedex Biotherapeutics Inc. appointed Joseph Tucker, Ph.D., a veteran biotechnology executive and current CEO of Enveric Biosciences, to its Board of Directors effective April 24, 2026. He will serve until the company’s 2027 annual meeting of stockholders, and will also join the Finance, Audit and Risk, Compensation, and Corporate Governance and Nominating Committees.
Under a board agreement, Dr. Tucker will attend at least two and up to four board meetings per year and be available for ad-hoc consultations. He will receive $6,000 per quarter in common stock and has been granted 33,784 warrants to purchase common stock at $10.00 per share, vesting in four equal tranches between October 2026 and April 2028 with a 10‑year term. The company highlights his experience raising over $100 million, leading public biotech companies, and executing IPOs, mergers, and acquisitions.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus registering the resale of up to 4,689,177 shares of common stock by identified stockholders in connection with a planned direct listing on the Nasdaq Capital Market. The resale is a secondary offering by existing holders; the Company will not receive proceeds from those resale transactions. The company has a binding private placement to sell 937,500 Series C Preferred Shares for aggregate gross proceeds of $7,500,000, convertible into Common Stock under specified pricing terms. The firm engaged RBW Capital Partners as financial advisor; RBW is expected to receive 272,219 advisory shares (1.75% of fully diluted shares) as compensation, which are not registered in this offering. The prospectus discloses recent short-term notes of $125,000 aggregate and summarizes 2025 net loss of $(3,847,637) with cash of $236,400 as of December 31, 2025.